Skip to main content

Phase 2 Start

TAK: Phase 2 Start: A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety an

September 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
September 1, 2026
Company
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 2 Start~month

Phase 2 Start: A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety an

TAK overview →
Indication
Antibody-Mediated Rejection (AMR)

Other upcoming events for TAK

Phase 3 ReadoutPhase 3 Topline: A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety
Phase 3 ReadoutPhase 3 Topline: A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line T